Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

November 1, 2021

Study Completion Date

November 1, 2023

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

anti-BCMA CAR-T

5×10\^7 /KG 15×10\^7 /KG 45×10\^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.

Trial Locations (1)

400037

RECRUITING

Department of Hematology, Xinqiao Hospital, Chongqing

Sponsors
All Listed Sponsors
collaborator

Carbiogene Therapeutics Co. Ltd.

INDUSTRY

lead

Xinqiao Hospital of Chongqing

OTHER

NCT04637269 - Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma | Biotech Hunter | Biotech Hunter